Healthcare Infection Control Practices Advisory Committee (HICPAC), 58397 [2012-23193]
Download as PDF
<![CDATA[
58397
Federal Register / Vol. 77, No. 183 / Thursday, September 20, 2012 / Notices
and CNF and these biomarkers of early
effect, considering potential
confounding factors such as smoking,
age, gender, and workplace coexposures, including non-engineered
ultrafine particles.
The proposed project supports the
NIOSH legislatively mandated
industrywide studies program that
conducts epidemiological and exposure
study will be carried out during the
participants’ regular work shift. There is
no cost to respondents or their
employers other than their time. We
estimate that the average burden per
response to be 22 minutes, and that the
total burden to all respondents will be
37 hours (see table below).
assessment research studies to identify
the occupational causes of disease in the
working population and their offspring
and to effectively communicate study
results to workers, scientists, industry,
and the public.
The questionnaire will be
administered one time only, at the
worksite, to 100 workers involved in the
production and use of CNT or CNT. The
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
responses per
respondent
Number of
respondents
Respondents
Average
burden per
response
(in hours)
Total burden
(in hours)
Nanomaterials Workers ...................................................................................
100
1
22/60
37
Total ..........................................................................................................
........................
........................
........................
37
Dated: September 14, 2012.
Ron A. Otten,
Director, Office of Scientific Integrity (OSI),
Office of the Associate Director for Science
(OADS), Office of the Director, Centers for
Disease Control and Prevention.
[FR Doc. 2012–23194 Filed 9–19–12; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Healthcare Infection Control Practices
Advisory Committee (HICPAC)
mstockstill on DSK4VPTVN1PROD with NOTICES
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting for the
aforementioned committee:
Times and Dates: 9:00 a.m.–5:00 p.m.,
October 11, 2012; 9:00 a.m.–12:00 p.m.,
October 12, 2012
Place: Renaissance Washington, DC
Dupont Circle Hotel, City Center Ballroom,
1143 New Hampshire Avenue NW.,
Washington, District of Columbia 20037.
Status: Open to the public, limited only by
the space available. Please register for the
meeting at www.cdc.gov/hicpac.
Purpose: The Committee is charged with
providing advice and guidance to the
Secretary, Department of Health and Human
Services (HHS); the Director, Centers for
Disease Control and Prevention (CDC); the
Deputy Director, Office of Infectious Diseases
(OID), CDC; and the Director, National Center
for Emerging and Zoonotic Infectious Disease
(NCEZID), CDC, regarding (1) the practice of
infection control; (2) strategies for
surveillance, prevention, and control of
healthcare-associated infections (e.g.,
nosocomial infections) antimicrobial
resistance and related events in settings
where healthcare is provided, including
VerDate Mar<15>2010
16:11 Sep 19, 2012
Jkt 226001
hospitals, ambulatory and long-term care
facilities, and home health agencies; and (3)
periodic updating of existing guidelines,
development of new guidelines, guideline
evaluation; and other policy statements
regarding the prevention of healthcareassociated infections an healthcare-related
conditions.
Matters To Be Discussed: The agenda will
include updates on CDC’s activities for
healthcare associated infections (HAI), an
update on the draft guideline for prevention
of infections among patients in neonatal
intensive care units (NICU), draft guideline
for the prevention of surgical site infections,
draft guidance for facility adjudication of
infection data, and an update from the
HICPAC surveillance working group.
Agenda items are subject to change as
priorities dictate.
Contact Person for More Information: Erin
Stone, M.S., HICPAC, Division of Healthcare
Quality Promotion, NCEZID, CDC, l600
Clifton Road, NE., Mailstop A–07, Atlanta,
Georgia 30333 Telephone (404) 639–4045.
Email: hicpac@cdc.gov
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Dated: September 12, 2012.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2012–23193 Filed 9–19–12; 8:45 am]
BILLING CODE 4163–18–P
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Advisory Committee to the Director
(ACD), Centers for Disease Control and
Prevention—Ethics Subcommittee (ES)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting of the
aforementioned subcommittee:
Time and Date: 8:30 a.m.–2:30 p.m., EDT,
Thursday, October 11, 2012.
Place: CDC, Thomas R. Harkin Global
Communications Center, Distance Learning
Auditorium, 1600 Clifton Road, NE., Atlanta,
GA 30333. This meeting is also available by
teleconference. Please dial (877) 928–1204
and enter code 4305992.
Status: Open to the public, limited only by
the space available. The meeting room
accommodates approximately 60 people. To
accommodate public participation in the
meeting, a conference telephone line will be
available. The public is welcome to
participate during the public comment
period. The public comment period is
tentatively scheduled for 2 p.m.–2:10 p.m.
Purpose: The ES will provide counsel to
the ACD, CDC, regarding a broad range of
public health ethics questions and issues
arising from programs, scientists and
practitioners.
Matters To Be Discussed: Agenda items
will include the following topics: Ethical
considerations relating to use of travel
restrictions for the control of communicable
diseases; addition of ethics standards to the
accreditation process for public health
departments; approaches for evaluating the
impact of public health ethics activities;
progress on developing practical tools to
assist state, tribal, local, and territorial health
departments in their efforts to address public
health ethics challenges; and strategies for
E:\FR\FM\20SEN1.SGM
20SEN1
]]>Agencies
[Federal Register Volume 77, Number 183 (Thursday, September 20, 2012)]
[Notices]
[Page 58397]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-23193]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Healthcare Infection Control Practices Advisory Committee
(HICPAC)
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces the following meeting for the aforementioned
committee:
Times and Dates: 9:00 a.m.-5:00 p.m., October 11, 2012; 9:00
a.m.-12:00 p.m., October 12, 2012
Place: Renaissance Washington, DC Dupont Circle Hotel, City
Center Ballroom, 1143 New Hampshire Avenue NW., Washington, District
of Columbia 20037.
Status: Open to the public, limited only by the space available.
Please register for the meeting at www.cdc.gov/hicpac.
Purpose: The Committee is charged with providing advice and
guidance to the Secretary, Department of Health and Human Services
(HHS); the Director, Centers for Disease Control and Prevention
(CDC); the Deputy Director, Office of Infectious Diseases (OID),
CDC; and the Director, National Center for Emerging and Zoonotic
Infectious Disease (NCEZID), CDC, regarding (1) the practice of
infection control; (2) strategies for surveillance, prevention, and
control of healthcare-associated infections (e.g., nosocomial
infections) antimicrobial resistance and related events in settings
where healthcare is provided, including hospitals, ambulatory and
long-term care facilities, and home health agencies; and (3)
periodic updating of existing guidelines, development of new
guidelines, guideline evaluation; and other policy statements
regarding the prevention of healthcare-associated infections an
healthcare-related conditions.
Matters To Be Discussed: The agenda will include updates on
CDC's activities for healthcare associated infections (HAI), an
update on the draft guideline for prevention of infections among
patients in neonatal intensive care units (NICU), draft guideline
for the prevention of surgical site infections, draft guidance for
facility adjudication of infection data, and an update from the
HICPAC surveillance working group.
Agenda items are subject to change as priorities dictate.
Contact Person for More Information: Erin Stone, M.S., HICPAC,
Division of Healthcare Quality Promotion, NCEZID, CDC, l600 Clifton
Road, NE., Mailstop A-07, Atlanta, Georgia 30333 Telephone (404)
639-4045. Email: hicpac@cdc.gov
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining
to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention
and the Agency for Toxic Substances and Disease Registry.
Dated: September 12, 2012.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2012-23193 Filed 9-19-12; 8:45 am]
BILLING CODE 4163-18-P
